Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander – IRPhillip Chan - ...

Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention ...

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the ...

Phillip Chan; Chief Executive Officer, Director; Cytosorbents Corp. Peter Mariani; Chief Financial Officer; Cyt ...

Solar and battery storage continue to shine as policy uncertainty awaits. We sell different types of products and services to both investment professionals and individual investors. These products ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-reports-fourth-quarter-and-full-year-2024-financial-results-and ...

CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the ...

CytoSorbents Corp. reported its fourth-quarter 2024 earnings, surpassing EPS expectations with an actual loss of $0.03 per share against a forecasted loss of $0.05. Despite lower-than-expected ...